InterventionsHuman trial

Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Type 2 Diabetes (SHINING-1)

ADA Scientific Sessions 2025 Abstract

The paper

Linong Ji, Leili Gao, Xiaolin Dong,

Xiaodan Huang, Xin Zhang, Yifeng Zheng, Chong Wang, Li Yan, SOLVD Investigators, Jing Li, Yun Peng, Haijun Li,

Xiaoxin Chen

Beijing

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 795-P

doi.org/10.2337/db25-795-p

A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026